Can a small startup compete on the big obesity stage? Resalis hopes to bring a new mechanism, and new benefits, to the fight against obesity.

Inozyme's CEO and chairman Douglas Treco shares his thoughts about the rousing success of the Orphan Drug Act, but cautions rare disease drug developers against sky high and inaccessible drug pricing practices.

Antiva Biosciences is exploring a local and global opportunity with a topically administered HPV treatment.

A novel small molecule developer aims to shake up the solid tumor treatment landscape.

Empress, launched by Flagship Pioneering, aims to harness AI and evolutionary biology to design the next generation of small molecule therapies.

Can a nested financial model help bring the next generation of neuroscience treatments to patients?

Founded in late 2019, KeifeRx is repurposing oncology drugs for neurodegenerative disorders.

A baker’s dozen of biopharma CEOs answer a call to prioritize and describe challenges they expect to face in the coming year.

Cardior Pharmaceuticals, led by CEO and cofounder Claudia Ulbrich, is developing what may be a much broader approach to heart failure, one that seeks to restore the diseased heart to its natural healthy state.

Freya Biosciences is enlivening the long-time lonely space of reproductive health, starting with a new focus on the vaginal microbiome.

When Dr. Scott Braunstein moved from his position as chairman of the board and interim CEO to become permanent CEO of Marinus Pharmaceuticals in August 2019, he had already concluded an overbroad focus was holding the company back.

Spruce Biosciences is currently in mid-to-late stage clinical development of new agents to treat rare endocrine disorders.

See why Nido Biosciences is developing small molecule drugs for rare neurodegenerative diseases.

Ketan Mehta, founder and CEO of Tris Pharma. Mehta came to the U.S. in the late 1970s. Since then, he has built a career in pharma and, more recently, an entirely new company with a triad of businesses — platform technology licensing, generic medicines, and new drug development.